Advance Technologies
Advance Technologies
批准号:
7473998
负责人:
Nigel Bourne
金额:
$93.8万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Basic ScienceBiological AssayCommunicable DiseasesCommunitiesConditionContainmentDevelopmentDiagnosticEnsureHealthHumanIndividualKnowledgeLifeMeasuresResearchResearch InfrastructureResearch PersonnelResourcesRoleRunningScreening procedureServicesSourceTechnologyTimeTranslatingValidationassay developmentbasecost effectivehigh throughput screeningimprovedin vitro Assaynovel therapeuticspathogenprogramstherapeutic target
中文摘要
高级技术核心(ATC)的中心职能将是支持GNL研究人员
将基础科学知识和发现转化为改善人类健康的实际措施。
在GNL进行的研究将确定许多新的潜在治疗和诊断目标
对抗威胁生命的传染病。在履行其中心职能时,空管将提供的第一项服务
将提供资源和专业知识,以开发利用这些新靶点和
技术,从研究工作台到标准的、可复制的和经过验证的适合
可用于中高通量筛选(HTS)研究。只要有可能,空管都会把
重点是开发能够在低遏制BSL2条件下进行的检测,这将
最大限度地提高其后续对研究界的效用。然而,并不是所有开发的分析都将是
适用于BSL2的使用,许多BSL2检测的有效验证将需要验证性研究
在BSL3或BSL4遏制下使用活病原体。因此,作为其体外试验开发的一部分
职能核心将不仅维持第二条线的遏制资源,而且将有资源进行
在BSL3和BSL4遏制条件下的检测进展。
空中交通管制将向西北环线提供的第二项服务将是基础设施,用于进行HTS研究
它开发的化验,或在BSL2和BSL3限制下现有的其他化验
在《蓝线4》围堵下进行小规模研究的额外能力。这项筛查计划将
为GNL研究人员提供识别活性化合物的能力,以作为开发
潜在的新疗法。
ATC的第三项主要服务将是协调GNL研究人员和
UTMB园区已有的专业研究中心的资源和专业知识。担任这一角色
空中交通管制将以两种不同的方式直接促进GNL的成本效益运行。首先,它将
确保国民总收入研究人员充分利用现有资源,而不是重复它们,
其次,它将最大限度地减少单个研究人员访问这些资源所涉及的时间和精力
作为单一来源访问点的临时基础。这将直接提高研究效率。
对于GNL来说。
英文摘要
The central function of the Advanced Technologies core (ATC) will be to support GNL researchers in
translating basic science knowledge and discoveries into practical measures to improve human health.
Research undertaken in the GNL will identify many new potential targets for therapeutics and diagnostics
against life threatening infectious diseases. In fulfilling its central function the first service that the ATC will
provide will be the resources and expertise to develop in vitro assays that utilize such new targets and
technologies, from the research bench top to a standardized, reproducible and validated format suitable that
can be used in medium to high throughput screening (HTS) studies. Wherever possible the ATC will place
emphasis on developing assays that can be conducted under low containment BSL2 conditions which will
maximize their subsequent utility to the research community. However, not all assays developed will be
suitable for BSL2 use and, effective validation of many of the BSL2 assays will require confirmatory studies
using live pathogens under BSL3 or BSL4 containment. Therefore, as part of its in vitro assay development
function the core will not only maintain BSL2 containment resources but will have the resources to conduct
assay development under BSL3 and BSL4 containment conditions.
The second service that the ATC will provide to the GNL will be infrastructure to conduct HTS studies using
the assays that it develops, or other already existing assays under both BSL2 and BSL3 containment with
the additional capacity to conduct small scale studies under BSL4 containment. This screening program will
provide GNL researchers with the ability to identify active compounds to serve as leads for development of
potential new therapeutics.
The third major service of the ATC will be to coordinate interactions between GNL researchers and those
resources and expertise in specialized research cores that already exist on the UTMB campus. In this role
the ATC will contribute directly to the cost effective running of the GNL in two distinct ways. Firstly, it will
ensure that GNL researchers make full use of existing resources rather than duplicating them and,
secondly, it will minimize the time and effort involved in individual researchers accessing these resources on
an ad hoc basis by acting as a single source point of access. This will directly increase research efficiency
for the GNL.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Therapeutic immunization to impact HSV-2 latency and associated pathogenesis
-
批准号:8731793
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2013
-
负责人:Nigel Bourne
-
依托单位:
Therapeutic immunization to impact HSV-2 latency and associated pathogenesis
-
批准号:8511197
-
项目类别:
-
资助金额:$18.15万
-
财政年份:2013
-
负责人:Nigel Bourne
-
依托单位:
Identification and Characterization of Novel Flavivirus Antivirals
-
批准号:7676476
-
项目类别:
-
资助金额:$13.47万
-
财政年份:2009
-
负责人:Nigel Bourne
-
依托单位:
Immunization to Reduce Genital and Neonatal Herpes
-
批准号:7788638
-
项目类别:
-
资助金额:$20.4万
-
财政年份:2009
-
负责人:Nigel Bourne
-
依托单位:
Identification and Characterization of Novel Flavivirus Antivirals
-
批准号:7649815
-
项目类别:
-
资助金额:$27.15万
-
财政年份:2008
-
负责人:Nigel Bourne
-
依托单位:
Advance Technologies
-
批准号:7262334
-
项目类别:
-
资助金额:$6.77万
-
财政年份:2006
-
负责人:Nigel Bourne
-
依托单位:
Morpholino Antisense Drugs for Hepatitis C Virus
-
批准号:6787453
-
项目类别:
-
资助金额:$16.41万
-
财政年份:2004
-
负责人:Nigel Bourne
-
依托单位:
Immunization to Reduce Genital and Neonatal Herpes
-
批准号:6700783
-
项目类别:
-
资助金额:$33.53万
-
财政年份:2003
-
负责人:Nigel Bourne
-
依托单位:
Immunization to Reduce Genital and Neonatal Herpes
-
批准号:6847825
-
项目类别:
-
资助金额:$33.53万
-
财政年份:2003
-
负责人:Nigel Bourne
-
依托单位:
Immunization to Reduce Genital and Neonatal Herpes
-
批准号:7011232
-
项目类别:
-
资助金额:$32.74万
-
财政年份:2003
-
负责人:Nigel Bourne
-
依托单位:
Immunization to Reduce Genital and Neonatal Herpes
-
批准号:6614354
-
项目类别:
-
资助金额:$13.41万
-
财政年份:2003
-
负责人:Nigel Bourne
-
依托单位:
Immunization to Reduce Genital and Neonatal Herpes
-
批准号:6521603
-
项目类别:
-
资助金额:$32.96万
-
财政年份:2002
-
负责人:Nigel Bourne
-
依托单位:
DRUG DEVELOPMENT FOR OPPORTUNISTIC INFECTIONS - CELL AND ANIMAL MODEL DEVELOPMEN
-
批准号:7543769
-
项目类别:
-
资助金额:$86.49万
-
财政年份:2002
-
负责人:Nigel Bourne
-
依托单位:--
Advance Technologies
-
批准号:8080175
-
项目类别:
-
资助金额:$214.29万
-
财政年份:--
-
负责人:Nigel Bourne
-
依托单位:
Advance Technologies
-
批准号:7665119
-
项目类别:
-
资助金额:$171.43万
-
财政年份:--
-
负责人:Nigel Bourne
-
依托单位:
海外基金